Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SynKIR-310 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT06544265Phase 1Recruiting
- Sponsor
- Verismo Therapeutics
- Start
- Nov 2024
- Primary completion
- Sep 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Synkir-310 in B-cell non-Hodgkin lymphoma, sponsored by Verismo Therapeutics. Primary endpoints: Safety of SynKIR310 up to 24 months and Recommended Phase 2 Dose up to 24 months. Started Nov 2024; status: recruiting.
02
Drugs
Synkir-310
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06544265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544265.